Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
- Conditions
- Chronic Graft Versus Host Disease cGVHD
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT03422627
- Locations
- 🇺🇸
Texas Oncology Baylor, Dallas, Texas, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇫🇷Hôpital Saint Louis, Paris Cedex 10, France
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT03410056
- Locations
- 🇪🇸
Research Site, A Coruña, Galicia, Spain
Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia
- Conditions
- Homozygous Familial Hypercholesterolemia HoFH
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT03403374
- Locations
- 🇮🇳
Research Site, Lucknow, Uttar Pradesh, India
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6
- Registration Number
- NCT03392064
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Other: Placebo
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 165
- Registration Number
- NCT03362177
- Locations
- 🇵🇹
Centro Hospitalar Universitario de Sao Joao, EPE - Hospital Sao Joao, Porto, Portugal
🇷🇺Autonomic SHI Republican clinical oncology dispensary of MoH of the Republic of Tatarstan, Kazan, Russian Federation
🇷🇺Clinical hospital 2, Group of companies medsi, Moscow, Russian Federation
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Other: PlaceboBiological: Romiplostim
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Amgen
- Registration Number
- NCT03343847
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Conditions
- Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT03340766
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT03335488
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇪🇸Hospital Materno-Infantil (HRU Carlos Haya), Málaga, Andalucia, Spain
🇮🇹Bambino Gesù Children's Research Hospital, Rome, Italy
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 269
- Registration Number
- NCT03319940
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic, Columbus, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇦🇹Landeskrankenhaus Salzburg, Salzburg, Austria
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT03318809
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States